Qube Research & Technologies LTD Nektar Therapeutics Transaction History

Qube Research & Technologies LTD

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.9 - $1.83 $24,795 - $50,418	-27,551 Reduced 62.82%	16,304 $20,000
Q1 2024 May 14, 2024	BUY	$0.49 - $0.96 $8,777 - $17,196	17,913 Added 69.05%	43,855 $40,000
Q4 2023 Feb 13, 2024	SELL	$0.42 - $0.57 $13,266 - $18,004	-31,586 Reduced 54.91%	25,942 $14,000
Q3 2023 Nov 13, 2023	SELL	$0.51 - $1.05 $163,643 - $336,913	-320,870 Reduced 84.8%	57,528 $34,000
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $200,550 - $389,749	378,398 New	378,398 $219,000
Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $110,472 - $232,917	54,420 New	54,420 $122,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $140,973 - $274,386	44,471 New	44,471 $169,000
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $407,431 - $787,269	-28,157 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.87 - $23.12 $446,851 - $650,989	28,157 New	28,157 $608,000
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $155,656 - $333,865	-9,205 Closed	0 $0
Q2 2019 Aug 02, 2019	BUY	$31.0 - $36.3 $285,355 - $334,141	9,205 New	9,205 $328,000
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $196,964 - $289,084	-6,237 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $14,880 - $27,701	-489 Reduced 7.27%	6,237 $205,000
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $312,489 - $460,663	6,726 New	6,726 $410,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.